Although DT delivered solid revenue growth in Q2, the group EBIT fell short of our low expectations.
Scanfil’s Q2 results came in somewhat higher than estimated.
Following the FDA approval in 17th February earlier this year FILSPARI is recording sales of USD 3m...
CapMan's Q2 2023 EBIT fell short of Refinitiv consensus expectations, partly explained by fair value...
Following BankNordik's Q2 2023 report, we leave 2023E-25E adjusted EPS roughly unchanged.
• EBITDA PLN 60-70m vs. ABGSCe PLN 112m • Miss driven by weaker paper volumes • Destocking likely to...
SDS har stuvat om affärsstrategin med ett större fokus på att leverera standardiserad mjukvara, snar...
Redeye comments on yesterday’s ruling in the lawsuit - in which the judge ruled that the whole paten...
Redeye saw a report that was roughly in line with our expectations.
DT posted Q2 net sales in line with our expectations, while adj.
Q2 NII came in 2% above our estimate at DKK 86m while NCI came in at DKK 19m versus our estimate at ...
CapMan's net sales in Q2 amounted to EUR 16.5m, below our estimates and below consensus (EUR 18.
CapMan reported Q2 EBIT of 4.2m, clearly below Refinitiv consensus at EUR 10.
Redeye updates on Xspray Pharma following its Q2 2023 report.
Redeye updates on Better Collective ahead of its Q2-results (due 22 August after market close) where...
Waystream redovisade minskad omsättning och resultat under Q2.
Redeye comments on the outcome of Nitro Games’ rights issue, which was subscribed to 60%, bringing c...
On 1 August, Relais announced the acquisition of NDS Group's Norwegian workshop equipment unit, whic...
Redeye gives its view on the financing commitments of up to USD20m with Negma Group.
• Solid growth, but high costs still hurting margins • More benefits from savings program in Q3e • 1...
